Variantyx

Variantyx is a molecular diagnostics company that provides genetic testing for rare genetic disorders, reproductive genetics, and precision oncology, disrupting the traditional testing approach with advanced proprietary technology built on a whole-genome platform. The company's Genomic Unity platform offers comprehensive test options ranging from targeted panels to whole-genome analyses, all performed on a single whole-genome sequencing infrastructure that enables automatic reflex testing from targeted to comprehensive analysis without additional sample collection or sequencing. Test categories include rare genetic disorders covering whole-genome, exome plus, exome, CNV, and mitochondrial analyses; neurology analyses for ataxia, dementia, epilepsy, motor neuron disorders, movement disorders, muscular dystrophy, neuropathies, and X-linked intellectual disability; rapid genome testing with Lightning analyses for NICU and standard settings; reproductive genetics including CNV and comprehensive analyses; precision oncology with hereditary cancer panels; and wellness testing through Genomic Inform. Variantyx's platform analyzes up to 45 genes for tandem repeat expansions and provides ACMG secondary and actionable incidental findings. The company emphasizes the highest diagnostic yield through superior technology, flexible reflex options, and shortening the diagnostic odyssey for patients. Case studies demonstrate the platform's ability to detect findings missed by other testing approaches, including DMD inversions, single exon PEX1 deletions confirming Zellweger spectrum disorder, and biallelic FGF14 expansions explaining progressive gait imbalance. The company offers insurance, institutional, and self-payer billing options with patient assistance programs.